Clinical Trial Record

Return to Clinical Trials

Psychological and Emotional Impact in Patients Undergoing Treatment For Metastatic Cancer Either in a Clinical Trial or as Standard Off-Trial Therapy


2007-09


2010-09


2010-11


200

Study Overview

Psychological and Emotional Impact in Patients Undergoing Treatment For Metastatic Cancer Either in a Clinical Trial or as Standard Off-Trial Therapy

RATIONALE: Gathering information from patients who received treatment for metastatic cancer while participating in a phase II or phase III randomized clinical trial and from patients receiving standard treatment off-trial may help doctors learn more about the psychological and emotional results of being in a clinical trial. PURPOSE: This clinical trial is comparing the psychological and emotional impact of participating in a randomized clinical trial with the impact of standard treatment in patients with metastatic cancer.

OBJECTIVES: Primary * To compare the psychological and emotional consequences in patients who underwent first-line antitumor treatment (chemotherapy or targeted therapy) for metastatic disease while participating in a phase II or III randomized clinical trial vs patients who underwent standard first-line treatment off-trial. Secondary * To measure and compare the temporal variation of psychological and emotional consequences during and after completion of or stopping of treatment. * To measure and compare the degree of knowledge of the implications of participating in a clinical study vs the benefits of standard off-trial treatment and evaluate the impact on psychological and emotional experience. * To evaluate the relationship between the use of adjustment strategies and emotional regulation and psychological and emotional experiences in both of these situations. OUTLINE: This is a multicenter study. Patients complete four questionnaires, including assessment of symptoms of anxiety and depression (HADS), quality of life (QLQ-30), adjustment strategies (WCC), and regulation of emotional behavior (ERQ), during their first course of treatment, after the first evaluation of treatment effectiveness, and one week after completion of treatment. During their first evaluation, patients also complete a questionnaire on the modalities of randomized clinical trials and their impact on care (ICEC-R).

  • Anal Cancer
  • Anxiety Disorder
  • Breast Cancer
  • Depression
  • Esophageal Cancer
  • Gallbladder Cancer
  • Gastric Cancer
  • Kidney Cancer
  • Liver Cancer
  • Lung Cancer
  • Pancreatic Cancer
  • Small Intestine Cancer
  • OTHER: questionnaire administration
  • PROCEDURE: psychosocial assessment and care
  • PROCEDURE: quality-of-life assessment
  • COL-0701
  • CDR0000626737 (REGISTRY Identifier) (REGISTRY: PDQ (Physician Data Query))
  • COL-IPSY
  • COL-RCB 2007-A00223-50
  • INCA-RECF0480

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates Results Reporting Dates Study Record Updates

2009-05-08  

N/A  

2013-07-09  

2009-05-08  

N/A  

2013-07-10  

2009-05-11  

N/A  

2009-07  

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Design Details

Primary Purpose:
N/A


Allocation:
N/A


Interventional Model:
N/A


Masking:
N/A


Arms and Interventions

Participant Group/ArmIntervention/Treatment
Primary Outcome MeasuresMeasure DescriptionTime Frame
Quality of life as assessed by the QLQ-30 questionnaire
Symptoms of anxiety and depression as assessed by the HADS questionnaire
Adjustment strategies and emotional regulation as assessed by the WCC and ERQ questionnaires
Secondary Outcome MeasuresMeasure DescriptionTime Frame

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person’s general health condition or prior treatments.

Ages Eligible for Study:
ALL

Sexes Eligible for Study:
18 Years

Accepts Healthy Volunteers:

    DISEASE CHARACTERISTICS:

  • Histologically confirmed cancer


  • Metastatic disease for which the median progression-free survival is ≥ 4 months
  • Breast, digestive, kidney, lung
  • Receiving first-line antitumor therapy (i.e., chemotherapy or targeted therapy) as part of either:


  • Phase II or III randomized clinical trial
  • Standard treatment off-trial

  • PATIENT CHARACTERISTICS:

  • WHO performance status (PS) 0-3 or Karnofsky PS 50-100%
  • No psychological or physical inability to respond to a questionnaire

  • PRIOR CONCURRENT THERAPY:

  • See Disease Characteristics
  • No psychotropic treatment, except for antidepressants, anxiolytics, or sleeping pills taken for more than 30 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.


    • : Stephanie Clisant, Centre Oscar Lambret

    Publications

    The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

    General Publications

    No publications available